Prostate Cell News Volume 4.44 | Nov 15 2013

Integrin-Free Tetraspanin CD151 Can Inhibit Tumor Cell Motility upon Clustering and Is a Clinical Indicator of Prostate Cancer Progression
Scientists demonstrated that CD151 can regulate tumor cell migration without direct integrin binding and that integrin-free CD151 (CD151free) correlates clinically with tumor progression and metastasis. Clustering CD151free through its integrin-binding domain promotes accumulation in areas of cell-cell contact leading to enhanced adhesion and inhibition of tumor cell motility in vitro and in vivo. [Cancer Res] Abstract

A Novel Carboxymethyl Chitosan-Quantum Dot-Based Intracellular Probe for Zn²⁺ Ion Sensing in Prostate Cancer Cells
Researchers fabricated novel carboxymethyl chitosan-coated CdTe quantum dots (CMC-CdTe QDs) via the electrostatic interaction between amino groups in the carboxymethyl chitosan polymeric chains and carboxyl groups of the CdTe QDs. They indicated that the CMC-CdTe QDs possess favorable cell compatibility, good sensitivity and selectivity for intracellular Zn²⁺ sensing. [Acta Biomater] Abstract

HDAC Inhibitor Confers Radiosensitivity to Prostate Stem-Like Cells
Considering prostate cancer heterogeneity, scientists hypothesized that primitive stem-like cells may constitute a radiation-resistant fraction. Primary cultures were derived from patients undergoing resection for prostate cancer or benign prostatic hyperplasia. [Br J Cancer] Abstract

Peroxidase-Like Activity of Fe₃O₄@Carbon Nanoparticles Enhancing Ascorbic Acid-Induced Oxidative Stress and Selective Damage to PC-3 Prostate Cancer Cells
In vitro experiments for human prostate cancer PC-3 cells demonstrated that Fe₃O₄@C-folic acid nanoparticles serve as peroxidase mimic to create hydroxyl radicals from the source of endogenous H₂O₂ that is yielded by exogenous ascorbic acid via an oxidative stress process. [ACS Appl Mater Interfaces] Abstract

Characterization and Sub-Cellular Localization of SS1R, SS2R, and SS5R in Human Late-Stage Prostate Cancer Cells: Effect of Mono- and Bi-Specific Somatostatin Analogs on Cell Growth
PC-3 and DU-145 human castration-resistant prostate cancer cells were found to express all somatostatin receptors (SSRs), while LNCaP expressed all but SS4R. [Mol Cell Endocrinol] Abstract

A Bufadienolide Derived Androgen Receptor Antagonist with Inhibitory Activities against Prostate Cancer Cells
Δ8,14-anhydrobufalin was found to show more potent inhibitory activity against the androgen dependent LNCaP cancer cells than the androgen independent PC3 cancer cells, but exhibited less inhibition on the Na⁺/K⁺ ATPase as compared with the parent bufalin. [Chem Biol Interact] Abstract

The Gastrin/Cholecystokinin-B Receptor on Prostate Cells – A Novel Target for Bifunctional Prostate Cancer Imaging
Scientists examined the gastrin/cholecystokinin-B receptor as a possible target for prostate-specific detection using the C-terminal seven amino acid sequence of the gastrin peptide hormone. [Eur J Pharm Sci] Abstract

Suppression of SCIN Inhibits Human Prostate Cancer Cell Proliferation and Induces G0/G1 Phase Arrest
To address the function of SCIN in prostate carcinoma cells, scientists used lentivirus-mediated RNAi to knock down SCIN expression in PC3 cells, a prostate carcinoma cell line. They found that in vitro silencing of SCIN could inhibit the proliferation and colony formation ability of PC3 cells. [Int J Oncol] Abstract

Pharmacological Characterization of N1-(2-Methoxyphenyl)-N4-Hexylpiperazine as a Multi-Target Antagonist of α_1A/α_1D-Adrenoceptors and 5-HT_1A Receptors that Blocks Prostate Contraction and Cell Growth
Scientists investigated the pharmacological characteristics of N1-(2-methoxyphenyl)-N4-hexylpiperazine. Using the DU-145 prostate cells, control experiments characterized the α_1D-adrenoceptor- and 5-HT_1A receptor-mediated cell growth by phenylephrine and 5-HT, respectively. [Naunyn Schmiedebergs Arch Pharmacol] Abstract

CLINICAL RESEARCH

Docetaxel and Dasatinib or Placebo in Men with Metastatic Castration-Resistant Prostate Cancer (READY): A Randomized, Double-Blind Phase III Trial
The authors assessed whether dasatinib plus docetaxel in chemotherapy-naive men with metastatic castration-resistant prostate cancer led to greater efficacy than with docetaxel alone. In this double-blind, randomized, placebo-controlled Phase III study, they enrolled men of 18 years or older with chemotherapy-naive, metastatic, castration-resistant prostate cancer, and adequate organ function from 186 centers across 25 countries. [Lancet Oncol] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.

Nutranomics Completes GenEpic™ Prostate Cancer Human Clinical Study Due Diligence Review
Nutranomics, Inc. provided an update regarding the GenEpic™ prostate cancer human clinical study that is currently underway. Nutranomics has previously announced a non-binding Letter of Intent with Genesar Nutraceuticals, LLC with the intent of completing a licensing agreement to market and distribute GenEpic™ globally. [PR Newswire Association LLC] Press Release

New wallchart from our sponsor: Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Postdoctoral Fellow – Development and Progression of Prostate Cancer (University of Maryland Baltimore, School of Medicine)

Postdoctoral Fellow / Instructor Position – Endocrine Therapies for Cancer (Baylor College of Medicine)

Experienced Researcher Position – Molecular Biology (ServiceXS B.V.)

Research Technician Position – Steroid Receptor Signaling (Baylor College of Medicine)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.